Company profile LPCN

Lipocine Inc
lipocine inc., a specialty pharmaceutical company, develops and commercializes pharmaceutical products. the company develops drugs based on hydroance, a drug delivery technology. it primarily focuses on developing oral versions of several hormones for use in men and women health. the company’s lipid-based technology platform offers non-invasive delivery solutions for small po...lar organics and macromolecules. it also offers custom drugs for pharmaceutical/biotechnology companies. lipocine inc. was founded in 1997 and is headquartered in salt lake city, utah. Show More
Quarter analysis & expected interest

There is not enough data for Lipocine (LPCN) stock to provide analysis

Correlation between past revenue and Lipocine (LPCN) stock search interest

There is not enough data for Lipocine (LPCN) stock to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Lipocine (LPCN) stock to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 09 2024 09:48:31.

After 39 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 52 days it will total up to 0.0.
Lipocine news expected interest is significantly lower compared to previous quarter (-100.0%) and same quarter last year (-100.0%).

YearQ1Q2Q3Q4
20190
88
inf% QoQ
52
-40.9% QoQ
35
-32.7% QoQ
2020 39
inf% YoY 11.4% QoQ
62
-29.5% YoY 59.0% QoQ
387
644.2% YoY 524.2% QoQ
128
265.7% YoY -66.9% QoQ
2021 265
579.5% YoY 107.0% QoQ
82
32.3% YoY -69.1% QoQ
114
-70.5% YoY 39.0% QoQ
57
-55.5% YoY -50.0% QoQ
2022 33
-87.5% YoY -42.1% QoQ
67
-18.3% YoY 103.0% QoQ
93
-18.4% YoY 38.8% QoQ
106
86.0% YoY 14.0% QoQ
2023 82
148.5% YoY -22.6% QoQ
31
-53.7% YoY -62.2% QoQ
17
-81.7% YoY -45.2% QoQ
57
-46.2% YoY 235.3% QoQ
2024 0
-100.0% YoY -100.0% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Lipocine news search interestLast update: February 09 2024 09:48:30.
Correlation coefficient between keyword and revenue is -0.18
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 09:48:34.

The average 5 years interest of Lipocine news was 6.88 per week.
The last year interest of Lipocine news compared to the last 5 years has changed by -47.67%.
This is something to be checked.
The last year interest is comparable to 5 years ago. It has changed only by 6.82%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Lipocine pipeline to provide analysis

Correlation between past revenue and Lipocine pipeline search interest

There is not enough data for Lipocine pipeline to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Lipocine pipeline to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 09 2024 09:48:40.

After 39 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 52 days it will total up to 0.0.
Lipocine TLANDO expected interest is significantly lower compared to previous quarter (-100.0%) and same quarter last year (-100.0%).

YearQ1Q2Q3Q4
201980
83
3.8% QoQ
16
-80.7% QoQ
84
425.0% QoQ
2020 56
-30.0% YoY -33.3% QoQ
56
-32.5% YoY 0.0% QoQ
83
418.8% YoY 48.2% QoQ
100
19.0% YoY 20.5% QoQ
2021 158
182.1% YoY 58.0% QoQ
14
-75.0% YoY -91.1% QoQ
57
-31.3% YoY 307.1% QoQ
42
-58.0% YoY -26.3% QoQ
2022 140
-11.4% YoY 233.3% QoQ
0
-100.0% YoY -100.0% QoQ
49
-14.0% YoY inf% QoQ
0
-100.0% YoY -100.0% QoQ
2023 55
-60.7% YoY inf% QoQ
105
inf% YoY 90.9% QoQ
75
53.1% YoY -28.6% QoQ
50
inf% YoY -33.3% QoQ
2024 0
-100.0% YoY -100.0% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Lipocine TLANDO search interestLast update: February 09 2024 09:48:39.
Correlation coefficient between keyword and revenue is -0.05
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 09:48:42.

The average 5 years interest of Lipocine TLANDO was 4.99 per week.
The last year interest of Lipocine TLANDO compared to the last 5 years has changed by 9.82%.
This is something to be checked.
The last year interest is comparable to 5 years ago. It has changed only by -10.6%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Lipocine testosterone replacement therapy to provide analysis

Correlation between past revenue and Lipocine testosterone replacement therapy search interest

There is not enough data for Lipocine testosterone replacement therapy to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Lipocine testosterone replacement therapy to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Lipocine CNS disorders to provide analysis

Correlation between past revenue and Lipocine CNS disorders search interest

There is not enough data for Lipocine CNS disorders to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Lipocine CNS disorders to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Lipocine postpartum depression to provide analysis

Correlation between past revenue and Lipocine postpartum depression search interest

There is not enough data for Lipocine postpartum depression to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Lipocine postpartum depression to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Lipocine testosterone laurate to provide analysis

Correlation between past revenue and Lipocine testosterone laurate search interest

There is not enough data for Lipocine testosterone laurate to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Lipocine testosterone laurate to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Lipocine cirrhosis management to provide analysis

Correlation between past revenue and Lipocine cirrhosis management search interest

There is not enough data for Lipocine cirrhosis management to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Lipocine cirrhosis management to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Lipocine non-alcoholic steatohepatitis to provide analysis

Correlation between past revenue and Lipocine non-alcoholic steatohepatitis search interest

There is not enough data for Lipocine non-alcoholic steatohepatitis to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Lipocine non-alcoholic steatohepatitis to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for LPCN
Earnings date: 2024-03-08 After close
Earnings date: 2024-03-08 After close
Company name: Lipocine Inc
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-05-07T16:05:00-04:00

PR Newswire
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026

2026-04-06T12:56:38Z

Analyst Upgrades
This Carvana Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday

2026-04-06T12:06:41Z

Analyst Upgrades
HC Wainwright & Co. Downgrades Lipocine to Neutral

2026-04-02T08:00:00-04:00

PR Newswire
Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression

2026-03-10T08:00:00-04:00

PR Newswire
Lipocine Announces Financial Results for the Full Year Ended December 31, 2025

2026-02-18T08:00:00-05:00

PR Newswire
Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD)

2026-01-21T11:31:47Z

Analyst Upgrades
HC Wainwright & Co. Maintains Buy on Lipocine, Raises Price Target to $15

2026-01-20T08:00:00-05:00

PR Newswire
Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

2026-01-19T17:20:49Z

GlobeNewswire
2026 Asset Growth: Why Federal Compliance Is the New Metric

2026-01-12T08:00:00-05:00

PR Newswire
Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

2025-12-16T08:00:00-05:00

PR Newswire
Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone

2025-11-18T08:00:00-05:00

PR Newswire
Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

2025-11-13T12:55:02Z

Analyst Upgrades
HC Wainwright & Co. Maintains Buy on Lipocine, Lowers Price Target to $7

2025-11-06T08:00:00-05:00

PR Newswire
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025

2025-11-04T08:00:00-05:00

PR Newswire
Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek®